1. Home
  2. Companies
  3. NSB
  4. Material Events

Neuroscientific Biopharmaceuticals (ASX:NSB) — Material Events

ASX:NSB · 10 articles in the last 12 months · 100% assessed

Click a band to jump to that tier

Significant 9 articles Notable 1 article Not Assessed 0 articles
Major ≥90 Significant 75–89 Notable 50–74 Routine <50 Not assessed
Significant Score 75–89
9
FDA backs NSB’s StemSmart Phase 2 trial design for refractory Crohn’s diseaseHigh
FDA supports NSB's planned Phase 2 StemSmart Crohn's disease trial
13 Oct 2026 ·Clinical Trial and Regulatory Update ·Unexpected ·86
NeuroScientific’s StemSmart™ Shows Promise in Tough Crohn’s CasesMedium
NeuroScientific reports positive clinical responses in Crohn's disease patients treated with StemSmart™ under Special Access Program
13 Jan 2026 ·ASX Announcement ·85
NeuroScientific Advances StemSmart Clinical Program and Manufacturing Scale-UpMedium
NeuroScientific reports positive StemSmart clinical results, advances manufacturing and Phase 2 trial plans
30 Apr 2026 ·Quarterly Activities Report ·85
Not Assessed Low Score, or missing data
0

No articles in this tier for the last 12 months.